CAUTION: Federal law (USA) restricts this device to sale by or on the order of a licensed practitioner.

Prior to use, please refer to all applicable “Instructions for Use” for more information on Intended Use/Indications for Use, Contraindications, Warnings, Precautions, Potential Adverse Events, and Operator’s Instructions.

INTENDED USE/INDICATIONS FOR USE

Percutaneous rotational coronary atherectomy with the ROTAPRO Rotational Atherectomy System, as a sole therapy or with adjunctive percutaneous coronary intervention (PCI) is indicated in patients with calcific coronary artery disease who meet one of the following selection criteria:

• Single vessel atherosclerotic coronary artery disease with a stenosis that can be passed with a guidewire;
• Multiple vessel coronary artery disease that in the physician’s judgment does not pose undue risk to the patient;
• Patients who have had prior PCI, and who have native coronary artery post-balloon angioplasty restenosis; or
• Native vessel atherosclerotic coronary artery disease that is less than 25 mm in length.

CONTRAINDICATIONS AND RESTRICTIONS

Contraindications

• Stenoses through which a guidewire will not pass.
• Last remaining vessel with compromised left ventricular function.
• Saphenous vein grafts.
• Angiographic evidence of thrombus.
• Angiographic evidence of significant dissection at the treatment site.

Restrictions

Rotational atherectomy should be performed only by physicians trained in percutaneous interventional procedures.

WARNINGS

• If the ROTAPRO Advancer or RotaLink Catheter shows evidence of mechanical failure at any time prior to or during the atherectomy procedure, immediately discontinue use of the device and return it to Customer Service for evaluation. Do NOT attempt to use a damaged ROTAPRO Advancer or RotaLink Catheter; use may result in device malfunction and/or patient injury.
• Never operate the ROTAPRO System without saline infusing. Flowing saline is essential for cooling and lubricating the working parts of the advancer. Operating the advancer without proper saline infusion may result in permanent damage to the ROTAPRO Advancer.
• Never operate the ROTAPRO Advancer in Dynaglide™ mode or operate the guidewire brake defeat button unless you have a firm grip on the guidewire using the wireClip™ torquer. The wireClip torquer may be held with the fingers or inserted completely into the docking port after the brake button is depressed. Defeating the brake, or operating the ROTAPRO Advancer in Dynaglide mode, without securing the guidewire may result in rotation and entanglement of the guidewire.
• During setup of the ROTAPRO System never grip or pull on the flexible shaft.
• Never advance the rotating burr to the point of contact with the guidewire spring tip. Such contact could result in distal detachment and embolization of the tip.
• If the ROTAPRO Advancer stops and the red STALL indicator on the console illuminates, retract the burr and immediately discontinue treatment. Check the advancer for proper connection to the console. If the connections are correct, use fluoroscopy to analyze the situation. Never force the system when rotational or translational resistance is encountered, as guidewire or vessel damage (such as perforation) may occur.
• Never advance the rotating burr by advancing the sheath. Guidewire buckling may occur and perforation or vascular trauma may result. Always advance the rotating burr by using the advancer knob.
• If resistance is encountered, retract the burr and stop treatment immediately. Use fluoroscopy to analyze the situation. Never force the ROTAPRO™ Advancer when rotational or translational resistance occurs, as vessel perforation, vessel trauma or embolism due to burr detachment or fractured wire may occur and in rare instances may result in surgical intervention and death.
• The use of ROTAPRO for in-stent restenosis might lead to damage of stent components and/or ROTAPRO System, which may lead to patient injury.
• Do not attempt to treat lesion while the ROTAPRO System is in Dynaglide™ mode. Always keep the burr advancing or retracting while it is rotating. Maintaining the burr in one location while it is rotating may lead to excessive tissue removal or entrapment to the ROTAPRO System. It is best to advance and retract the burr no more than 3 cm at a time in a smooth pecking motion, being careful to engage the lesion only minimally when resistance is met. Short individual runs of less than 30 seconds are recommended with total rotational procedure time not to exceed five minutes.

PRECAUTIONS

• Treating certain types and/or locations of lesions or patients with certain conditions is inherently riskier, regardless of the therapeutic device being used. Physicians should be aware of the higher risk when treating patients, such as:
  1. Patients who are not candidates for coronary artery bypass surgery;
  2. Patients with severe, diffuse three-vessel disease (multiple diseased vessels should be assessed for treatment in separate sessions);
  3. Patients with unprotected left main coronary artery disease;
  4. Patients with ejection fraction less than 30 %;
  5. Lesions longer than 25 mm;
  6. Angulated (≥ 45°) lesions.

POTENTIAL ADVERSE EVENTS

Potential adverse reactions which may result from the use of this device include but are not limited to:

• Angina
• Arrhythmias
• Bailout stenting
• Conduction block
• Death
• Drug reaction, allergic reaction to contrast media
• Electric shock
• Embolism (coronary, cerebral, peripheral)
• Hemorrhage or hematoma
• Infection, local or systemic
• Myocardial ischemia
• Myocardial infarction
• Pericardial effusion/cardiac tamponade
• Pulmonary edema/cardiogenic shock
• Slow flow, no reflow, abrupt vessel closure
• Stroke
• Thrombus formation
• Vessel spasm
• Vessel trauma (dissection, perforation, rupture or injury)

There may also be complications associated with distortion, kinks, and fracture of the guidewire and physical deterioration or malfunction of the system, which can lead to patient injury or death. In addition, some of the above potential adverse events may require additional surgical intervention.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.

INTENDED USE

The ROTAPRO Console is intended for use with the ROTAPRO Rotational Atherectomy System. Refer to guidewire and advancer package inserts for specific information on the use of these components.

CONTRAINDICATIONS

No additional information is required for the section in the BSD.

WARNINGS

• Never use oxygen as the propellant for the ROTAPRO Rotational Atherectomy System. Never connect the regulator to an oxygen cylinder. Oxygen combined with oil or other combustibles in the system can result in a fire.
• The use of accessories, other than those specified, with the exception of those sold by the manufacturer of the ROTAPRO System as replacement parts for internal components, may result in increased emissions or decreased immunity of the ROTAPRO System.
• The ROTAPRO System should not be used adjacent to or stacked with other equipment. If adjacent or stacked use is necessary, the ROTAPRO System should be observed to verify normal operation in the configuration in which it will be used.
• This device is not to be used in the presence of flammable anesthetics.
• If a hissing noise is detected from the console, check to make sure that the pressure of the gas supplied to the air or nitrogen connector does not exceed 758.4 kPa (110 psi). The console is equipped with a pressure relief valve to protect against excessive inlet pressure. Do NOT operate the ROTAPRO Console with gas pressures in excess of 758.4 kPa (110 psi), as a gas hose may burst.
• If patient defibrillation becomes necessary, the physician should take the appropriate measures to protect themselves against electrocution from the defibrillator.
• Do not modify or repair beyond replacement of fuses as described in Service Information. Modification or repair of the instrument by a person other than an authorized Boston Scientific Representative may compromise the integrity of the device and/or lead to device failure which, in turn, may result in patient injury or death. Boston Scientific assumes no liability with respect to any instrument which has been modified or repaired by a person other than an authorized Boston Scientific Representative and makes no warranties, express or implied, including but not limited to merchantability or fitness for a particular purpose, with respect to such instruments. If repair is needed, call your Boston Scientific Representative.
• Following any change in console set-up or configuration, the ROTAPRO System should be observed to verify normal operation in the configuration in which it will be used.
• If the ROTAPRO System shows evidence of mechanical failure at any time prior to or during the Atherectomy procedure, immediately discontinue use of the device and contact your Boston Scientific Representative for evaluation. Do NOT attempt to use a damaged ROTAPRO System; use may result in device malfunction and/or patient injury.
• Use of this equipment adjacent to or stacked with other equipment should be avoided because it could result in improper operation. If such use is necessary, this equipment and the other equipment should be observed to verify that they are operating normally.
• Use only those accessories intended to be used with the ROTAPRO System.
• Use of accessories, transducers, and cables other than those specified or provided by the manufacturer of this equipment could result in increased electromagnetic emissions or decreased electromagnetic immunity of this equipment and result in improper operation.
• Portable RF (Radio Frequency) communications equipment (including peripherals such as antenna cables and external antennas) should be used no closer than 30 cm (12 inches) to any part of the ROTAPRO System, including cables specified by the manufacturer. Otherwise, degradation of the performance of this equipment could result.

PRECAUTIONS

• Care must be taken not to spill saline or other fluids on the console. Saline spilled in the console may result in corrosion or electrical hazard.
• The ROTAPRO™ Console requires special precautions regarding electromagnetic emissions and immunity and needs to be installed and put into service according to the electronic and electromagnetic guidance provided in Appendix E.
• Portable and mobile RF (Radio Frequency) communications equipment can affect the ROTAPRO Console.

ADVERSE EVENTS

Refer to guidewire and advancer instructions for use for specific information on potential adverse events.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

INTENDED USE/INDICATIONS FOR USE

The wireClip Torquer is an accessory component shipped with the guidewire and is also available separately. It is used for gripping and rotating the guidewire during placement. It must be used during the ablation procedure.

CONTRAINDICATIONS

Refer to the Rotablator System Rotalink Exchangeable Burr Catheter “Instructions for use” before using the wireClip Torquer during a Rotablator System rotational atherectomy procedure.

WARNINGS

Refer to the Rotablator System Rotalink Exchangeable Burr Catheter “Instructions for use” before using the wireClip Torquer during a Rotablator System rotational atherectomy procedure

PRECAUTIONS

Refer to the Rotablator™ System Rotalink™ Exchangeable Burr Catheter “Instructions for use” before using the wireClip™ Torquer during a Rotablator System rotational atherectomy procedure.

ADVERSE EVENTS

Refer to the Rotablator System Rotalink Exchangeable Burr Catheter “Instructions for use” before using the wireClip Torquer during a Rotablator System rotational atherectomy procedure.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

INDICATIONS FOR USE

Rotaglide lubricant is intended for use with the Rotablator or ROTAPRO atherectomy system, for the purpose ofincreasing the lubricity of the system. The Indications for Use of the Rotablator or ROTAPRO system remain unchanged.

CONTRAINDICATIONS

Rotaglide lubricant is contraindicated in patients with known allergies to the lubricant ingredients: olive oil, egg yolk phospholipids, glycerin, sodium deoxycholate, L-histidine, disodium EDTA, sodium hydroxide, and water.

WARNINGS

Always check the vial for cracks or leaks. Discard if any are found. Discard vial if there are particulates in the emulsion or if an oiling-out of emulsion has occurred.

PRECAUTIONS

Careful consideration should be given to additions of divalent cations (Ca++ and Mg++) which have been shown to cause emulsion instability.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

INTENDED USE/ INDICATIONS FOR USE

These guidewires are intended for use with the Rotablator or ROTAPRO Rotational Atherectomy System.

CONTRAINDICATIONS

Carefully read this document and refer to the Rotablator and ROTAPRO System Console “Operator’s Manual”, RotaLink™ Exchangeable Burr Catheter “Instructions for Use”, and ROTAPRO “Instructions for Use” observing all Contraindications, Restrictions, Warnings, and Precautions for specific information on the use of these components.

WARNINGS

The use of a ROTAWIRE Drive Guidewire may straighten a tortuous vessel such that it places the point of burr-vessel interaction on the lesser curvature of the vessel (burr bias) potentially inducing vasospasm and pseudostenoses that may result in perforation and/or dissection during rotational atherectomy treatment. Care needs to be taken to maintain coaxial alignment of the guide catheter and ROTAWIRE Drive Guidewire/burr assembly during ablation. Failure to do so may cause a transected ROTAWIRE Drive Guidewire that may result in embolism, myocardial infarction, dissection, and /or surgical intervention and in rare cases, death. Do not torque, advance or withdraw guidewire if significant resistance is felt. Torquing, advancing, or withdrawing guidewire under resistance may cause guidewire and/or vessel damage. Exercise care in handling of the ROTAWIRE Drive Guidewire during the procedure to reduce the possibility of accidental breakage, bending, kinking, coil separation, or loop making in the aorta. A tight loop, kink or sharp bend (greater than 90 degrees in the guidewire) may cause fracture during use. Resulting wire fracture may require additional percutaneous intervention or surgery.

PRECAUTIONS

The guidewire should not be advanced within vessels or stenoses with a narrower diameter than the spring tip to avoid guidewire and vessel damage. The distal spring tip is designed to not pass through the lumen of the burr catheter. The ROTAWIRE Drive cannot be withdrawn through the advancer. The advancer must be removed prior to ROTAWIRE Drive exchange.

Treating certain types and/or locations of lesions or patients with certain conditions is inherently riskier, regardless of the therapeutic device being used. Physicians should be aware of the higher risk when treating patients, such as:

1. Patients who are not candidates for coronary artery bypass.

2. Patients with severe, diffuse three-vessel disease (multiple diseased vessels should be treated in separate

sessions).

3. Patients with unprotected left main coronary artery disease.

4. Patients with ejection fraction less than 30%.

5. Lesions longer than 25 mm.

6. Angulated (≥ 45°) lesions.

7. Patients for whom anticoagulation is not indicated.

When performing percutaneous rotational atherectomy with the ROTAPRO System on-site surgical backup should be included as a clinical consideration.

ADVERSE EVENTS

Potential adverse reactions which may result from the use of ROTAWIRE™ Drive Guidewires, Rotablator, and ROTAPRO™ Systems include but are not limited to:

• Additional intervention or surgery
• Allergic reaction (contrast, device or other)
• Angina
• Arrhythmia
• Cerebral vascular accident/Transient ischemic attack
• Death
• Electric shock
• Embolism (air, device, plaque, thrombus, tissue, or other)
• Hemorrhage or hematoma
• Hypotension/hypertension (including cardiogenic shock)
• Infection/sepsis
• Myocardial ischemia or infarction
• Pericardial effusion /cardiac tamponade
• Pulmonary edema
• Vessel occlusion (slow flow, no reflow, abrupt vessel closure)
• Radiation injury
• Thrombosis/thrombus
• Vasospasm
• Vessel trauma (arteriovenous fistula, dissection, perforation, pseudoaneurysm, rupture or injury)

There may also be complications associated with distortion, kinks, and fracture of the guidewire and physical deterioration or malfunction of the device, which can lead to patient injury or death.

92673855 B.2